comparemela.com

Latest Breaking News On - Submits marketing authorisation application - Page 1 : comparemela.com

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.

Comunidad autonoma de catalunaRegion flamandeSan antonioUnited statesEurop urolJanssen pharmaceuticaTanakam sonpavdeClin pharmacolSabine brookmanHenar heviaIndianj urolAstex therapeuticsDrug administrationEuropean medicines agencyNone of janssen cilag internationalEuropean society for medical oncology

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2% and adjusted operational growth of 5.7% . Operational growth excluding COVID-19 Vaccine of.

Johnson medtechJoaquin duatoAshley mcevoyBiosense websterJohnson medtech acquires laminar incExchange commissionDevelopment expenseEuropean medicines agencyEuropean medicines agency seeking approval of lazertinibResearch development expenseConsumer health companyInterventional solutionsDrug administration grants full approvalCompany consumer healthChief executiveInnovative medicine

Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST

News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor.

Region flamandeUnited statesCatherine taylorKiran patelZayn qureshiJanssen research developmentJanssen biotech incEuropean unionJanssen pharmaceutical companies of johnsonClinical developmentNational cancer instituteAmerican lung associationEuropean society of medical oncologyJanssen researchEuropean medicines agencyCilag gmbh international

Johnson & Johnson : 2023 Third-Quarter Press Release & Supplemental Schedules -October 17, 2023 at 06:45 am EDT

Media contact: Investor contact: .

Joaquin duatoTesia williamsJessica mooreEuropean medicines agency seeking approvalExchange commissionDrug administration seekingEuropean academy of dermatologyFinalizes separation of kenvue incJohnson announces final results of exchangeJanssen highlights latest researchConsumer health companyTrueref technology for mappingNipocalimab clinical development program to address unmetConsumer healthInterventional solutionsJanssen to highlight latest research

Johnson & Johnson Reports Q3 2023 Results

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4% and adjusted operational growth of 4.9% . Operational growth excluding COVID-19 Vaccine of.

Joaquin duatoJanssen to highlight latest researchFinalizes separation of kenvue incJohnson announces final results of exchangeConsumer healthEuropean commission approvesInterventional solutionsCompany consumer healthEuropean society of retina specialistsExchange commissionEuropean medicines agency seeking approval of erdafitinibEuropean academy of dermatologyJanssen highlights latest researchConsumer health companyDrug administration seeking full approvalEuropean medicines agency

vimarsana © 2020. All Rights Reserved.